Skip to main content

Bio-Rad to Commercialize Visia Imaging's Immunofluorescence Slide Technology

NEW YORK (360Dx) – Bio-Rad Laboratories said on Tuesday that it has entered into an agreement that gives it commercialization rights to Visia Imaging's second-generation immunofluorescence slide processing and reading platform for the evaluation of autoimmune diseases.

Laboratories frequently employ immunofluorescence slides as a first step in screening for numerous autoimmune diseases, including systemic lupus erythematosus, Bio-Rad said.

Visia’s second-generation system integrates automated slide processing with reading of immunofluorescence slides, and Bio-Rad noted that the platform will be used to automatically process slides, capture images, and aid in the interpretation of immunofluorescence results. Offered alongside the BioPlex 2200 System, the technology will allow Bio-Rad to deliver a more comprehensive suite of automation solutions to the autoimmune laboratory, the firm said.

Bio-Rad President of Clinical Diagnostics John Hertia said in a statement that “The platform offers a standardized and automated workflow that is needed by laboratories to handle their ever-increasing [immunofluorescence] workloads."

Financial and other terms of the deal were not disclosed.